Sign Out
Women of childbearing potential: Women of childbearing potential must be advised not to get pregnant during therapy.
Pregnancy: There are no data from the use of Gefitinib in pregnant women. The potential risk for humans is unknown. Gefitinib should not be used during pregnancy unless clearly necessary.
Breast-feeding: It is not known whether Gefitinib is secreted in human milk. Gefitinib is contraindicated during breast-feeding and therefore breast-feeding must be discontinued while receiving Gefitinib therapy.
